NCT06920745

TriClip CED RWE Study

Recruiting
Not specifiedAges 18+Observational
Abbott Medical Devices
~2,200 participants
Updated 2025-08-11 on ClinicalTrials.gov
What's tested:The TriClip System

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Composite of heart failure hospitalization or all-cause mortality
Measured over 2 years
Tricuspid Regurgitation

NCT06920745

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Abbott

    Santa Clara, Californiastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients ≥ 18 years of age at time of implant
Patients with symptomatic, severe or greater Tricuspid Regurgitation who have received the TriClip system (treatment group) or have not undergone T-TEER (control group)

Exclusion

Patients with less than severe Tricuspid Regurgitation
Patients with a prior history of surgical or transcatheter tricuspid valve replacement
Patients with a surgical or transcatheter aortic or mitral valve intervention within 90 days prior to index
  • Composite of heart failure hospitalization or all-cause mortality2 years

    Compare the rate of composite endpoint at 2 years between the treatment and control groups.